New Protein Stability Technology Announced

BioPhysix (San Diego, CA) and University of Texas at Austin (UT-Austin) today announced important breakthroughs in the stabilization of therapeutic proteins that minimizes the loss of bioactivity and maintains physical properties at both elevated and freezing temperatures. Stabilized proteins also exhibit long-term stability at ambient temperatures.

Aimed at extending shelf life and eliminating restrictive and expensive storage conditions, these technologies open up third-world markets that have inadequate distribution and refrigeration facilities. It also helps alleviate expensive recalls and can be used to extend patent life. This stabilization technology also cuts the costs of administration, storage, and the costly disposal of therapeutics past their expiration date, benefiting hospital, government and country health administrations.

UT-Austin, in conjunction with BioPhysix, is presenting three posters on this patented Imprex™ technology at the upcoming American Association of Pharmaceutical Scientists (AAPS) convention in Salt Lake City (October 27-30). Model compounds studied have included both large and small protein drugs such as Bovine Serum Albumin (BSA) and Lysozyme, respectively, as well as unstable protein drugs such as Insulin and Calcitonin. The Imprexstabilization process generates both uniform sub-micron particles with specified sizes and liquid emulsions in an anhydrous environment. The resultant product is amiable to incorporation in microspheres and depot release formulas and into a host of needle-free delivery methods.

BioPhysix, in addition to the Imprex™ technology described above, is also the exclusive licensee of the Membrex™ technology from the University of Illinois at Chicago. Membrex is a powerful technology that uniquely facilitates inhalation, mucosal and other needle-free forms of delivery. BioPhysix is now co-venturing with companies who have early therapeutic protein stability issues, and companies looking to extend both patent life cycles and current shelf-life limitations.